Skip to main content
Premium Trial:

Request an Annual Quote

Cue Health Revenues up Massively in Q3

NEW YORK – Cue Health on Wednesday afternoon announced a massive year-over-year uptick in revenues for the third quarter, easily beating the consensus Wall Street expectation.

For the three months ended Sept. 30, the San Diego-based diagnostic test development company, which went public in September, posted $223.7 million in revenues compared to $4.7 million in Q3 a year ago. The analysts' average estimate was $200.3 million.

Product revenues were $222.6 million compared to $2.1 million in Q3 2020, while grant and other revenues decreased to $1.1 million from $2.6 million.

The company recorded public sector revenue of $129.5 million compared to $105 million in Q2 2021, an increase driven by additional deliveries to the US Department of Defense and the US Department of Health & Human Services under an existing agreement, Cue Health said.

It posted $94.2 million in private sector revenue, up from $32.4 million in the prior quarter, on "significant additions to the enterprise and provider customer base," the firm said.

Disposable test cartridge revenue in Q3 2021 was $179.0 million, up 74 percent from the prior quarter.

The company offers the Cue Health Monitoring System, which consists of a portable reader with a single-use test cartridge and a sample collection wand. Its COVID-19 Test Kit received Emergency Use Authorization from the US Food and Drug Administration last year for use by CLIA-certified labs or at the point of care.

The test also received EUA for home and over-the-counter use in March, making it the first molecular test authorized by the agency for home use without a prescription.

Cue Health had a net income of $19.3 million, or $.13 per share, in the recently completed quarter compared to a net loss of $8.5 million, or $.52 per share, in Q3 a year ago. The consensus Wall Street EPS estimate was $1.48.

The weighted-average number of shares used to compute net income per share in Q3 was 39.3 million, whereas it was 16.6 million in Q3 of 2020.

The company's R&D costs grew 32 percent year over year to $9.1 million from $6.9 million, while its SG&A expenses grew more than tenfold to $38.7 million from $3.7 million.

Cue Health exited the third quarter with $446.6 million in cash and cash equivalents and $12.0 million in restricted cash.

The company said full-year 2021 revenues are expected to be in the range of $580 million to $590 million.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.